New oral GLP-1 drugs can make treatment more convenient, but oral semaglutide and the small-molecule drug orforglipron reach the bloodstream in very different ways. Ben argues that regardless of delivery method, these medications are most valuable when used as a temporary tool to control carbohydrate cravings, lower insulin, and build habits that can ultimately reduce reliance on the drug.

Summary: In today’s mini-lecture, Dr. Ben Bikman explains the new generation of oral GLP-1 medications and why two drugs that come as pills can work very differently. Oral semaglutide is still a peptide, so it requires a special absorption enhancer to protect it from digestion and help it cross the stomach lining. Even then, only about 1% of the dose reaches the bloodstream, requiring strict instructions about taking it on an empty stomach. Orforglipron, by contrast, is a small molecule rather than a peptide, allowing it to survive digestion and be absorbed much more efficiently without the same restrictions.

Ben reviews studies comparing the drugs for blood glucose control, weight loss, side effects, and maintaining weight loss after injectable GLP-1 therapy. But he emphasizes that changing the delivery method does not change the underlying metabolic rules: insulin still governs whether fat is stored or released.

Most importantly, Ben argues that GLP-1 medications should be viewed as an opportunity to change metabolic habits rather than simply as long-term weight-loss drugs. Because they can temporarily reduce cravings for sweets and refined carbohydrates, he believes that window should be used to reduce those foods, emphasize protein and fat, and develop habits that can eventually provide an “off-ramp” from the medication..

generated summary

Pills and GLP-1 basics

  • The two oral GLP-1 weight-loss drugs now approved solve the same delivery problem in very different ways: oral semaglutide is still a peptide, while orforglipron is a small molecule; neither changes the basic metabolic rules governing fat storage and release.
  • GLP-1 is released from intestinal cells after food arrives. For obesity and weight loss, its most relevant effect is slower stomach emptying and therefore slower nutrient entry into the blood; appetite regulation in the brain is another possible mechanism, although evidence for its importance is debated.
  • Peptide GLP-1 drugs such as semaglutide, liraglutide, tirzepatide, and retatrutide are amino-acid chains made more stable than natural GLP-1, but stomach acid and digestive enzymes denature and break down peptides, so injection historically bypassed the digestive problem.

Oral semaglutide

  • Oral semaglutide keeps the peptide but packages it with the absorption enhancer SNAC. SNAC locally buffers stomach acidity, keeps semaglutide molecules from clumping, and temporarily increases passage across the stomach lining so some intact drug can enter the blood.
  • Absorption occurs through the stomach and remains extremely inefficient: only about 1% of the swallowed dose, sometimes closer to 0.5%, reaches the bloodstream. The tablet therefore has to be taken in the morning on an empty stomach with only a few ounces of water, followed by roughly 30 minutes without food or drink.
  • Oral semaglutide is essentially the injectable peptide adapted for swallowing through chemical assistance, with convenience traded for a strict dosing routine.

Orforglipron

  • Orforglipron abandons the peptide structure altogether. As a small molecule it survives digestion, activates the same GLP-1 receptor through a distinct binding site, and produces sufficiently similar signaling without needing an absorption enhancer.
  • A tracer study comparing oral with intravenous delivery found mean oral bioavailability of about 79%, roughly 80 times the oral absorption of semaglutide. [1]
  • Food can reduce orforglipron exposure by roughly one-fifth, but the reduction remains compatible with a meaningful physiological response, allowing once-daily dosing without fasting, waiting, or food restrictions. [2]

Clinical data

  • In a 26-week type 2 diabetes trial, orforglipron improved markers of insulin sensitivity: HOMA-IR fell by up to about one quarter by week 26, and adiponectin increased. [3]
  • The all-randomized analysis counts everyone assigned whether or not they stayed on the drug; it is more conservative and more reflective of real-world use than analysis limited to people who remained on it.
  • The main obesity trial enrolled about 3,000 adults without diabetes for 72 weeks. Weight fell about 7% at the low dose, 8.5% at the middle dose, and just over 11% at the highest dose, versus about 2% with placebo; among people who stayed on the highest dose, loss was a little over 12%. [4]
  • In type 2 diabetes, a head-to-head trial found orforglipron beat oral semaglutide on blood sugar and weight at the doses tested, but semaglutide was only 7 or 14 mg, not its 25 mg obesity dose, so this was not a comparison of normal weight-loss doses. [5]
  • Across separate obesity trials against placebo, oral semaglutide 25 mg produced about 13.5% weight loss and orforglipron about 11%; semaglutide produced somewhat more weight loss, while orforglipron was easier to take but had somewhat more nausea, vomiting, and diarrhea. [4][6]
  • In nearly 400 people who had reached a stable weight after injected semaglutide or tirzepatide, switching to orforglipron for a year preserved roughly 80-90% of the prior weight loss, whereas switching to placebo preserved only about half. [7]

Insulin, food, and GLP-1

  • The chemistry and delivery can change, but insulin still governs whether fat cells grow or shrink: while insulin stays elevated, stored fat stays stored. GLP-1 drugs help largely by reducing how much is eaten and slowing how quickly what is eaten reaches the blood, which lowers insulin.
  • Refined carbohydrate—flour, sugar, and processed starches—is the strongest dietary driver of insulin, so if the drug makes eating less easier, the food to reduce is refined carbohydrate.
  • About 30 years ago, women with obesity and age-matched lean women were given carbohydrate and fat meals and followed for three hours. The obese women had a markedly blunted GLP-1 response to carbohydrate but a more robust fat response closer to the lean women. [8]
  • The macronutrient that raises insulin the most can also fail to generate its normal GLP-1 satiety signal in obesity, leaving carbohydrate intake harder to regulate; a GLP-1 drug can help restore that missing signal.

Using the drug as a window for habit change

  • A two-year semaglutide trial measured food cravings over time. Cravings for sweets, refined starches, and sugars were markedly reduced around six months and remained reduced around one year, but by two years the cravings had returned to normal despite ongoing and escalating semaglutide dosing. [9]
  • This creates roughly a one-year window in which sugar and refined-carbohydrate foods exert less pull. Using the period merely to eat smaller portions of the same foods leaves the old habits intact; using it to build meals around fat and protein creates new habits before the cravings return.
  • GLP-1 drugs are a crutch that need not be permanent: they can help break carbohydrate cravings or addiction long enough to learn what control feels like, then provide an off-ramp through dose reduction and eventually stopping the drug.
  • Switching from an injectable peptide to oral orforglipron may eventually prove useful for cycling off therapy while preserving drug sensitivity, but that remains an open question for future studies.
  • The practical end point is unchanged by the new chemistry: use the drug to lower insulin by helping control carbohydrate cravings, then use the period of reduced cravings to build habits that can persist without the drug.

References

  1. [10:26] Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants — https://doi.org/10.1002/cpdd.1594
  2. [11:17] Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist — https://doi.org/10.1007/s13300-024-01554-1
  3. [12:13] Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes — https://doi.org/10.1111/dom.70022
  4. [13:38] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment — https://doi.org/10.1056/NEJMoa2511774
  5. [14:13] Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial — https://doi.org/10.1016/S0140-6736(26)00202-3
  6. [15:02] Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity — https://doi.org/10.1056/NEJMoa2500969
  7. [16:16] Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial — https://doi.org/10.1038/s41591-026-04386-7
  8. [18:53] Attenuated GLP-1 secretion in obesity: cause or consequence? — https://doi.org/10.1136/gut.38.6.916
  9. [20:48] Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5 — https://doi.org/10.1002/oby.23673

no comments (yet)

sorted by: hot top controversial new old
there doesn't seem to be anything here